Lexaria Bioscience Secures $4 Million in Financing to Advance 2026 Research and Development Initiatives

Lexaria Bioscience Corp. has announced the closing of a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The company sold 2,666,667 shares of common stock at $1.50 per share, generating aggregate gross proceeds of approximately $4.0 million before deducting placement agent fees and other offering expenses. In a concurrent private placement, Lexaria issued unregistered warrants to purchase up to 2,666,667 additional shares of common stock with an exercise price of $1.37 per share.

Chief Executive Officer Richard Christopher stated that this financing provides greater optionality for the company's 2026 research and development and business development plans. Christopher emphasized that most of Lexaria's study work requires signed contracts before initiation, necessitating constant evaluation of future funding requirements. The financing enables the company to bring its 2026 plans into focus and execute on R&D initiatives that drive intellectual property development and overall company value.

H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2025. The registered direct offering was made only by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement available at https://www.sec.gov.

The warrants issued in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. These warrants, along with the underlying shares of common stock, have not been registered under the Securities Act or applicable state securities laws. Accordingly, they may not be offered or sold in the United States except pursuant to an effective registration statement or applicable exemption from registration requirements.

This financing represents a strategic move to strengthen Lexaria's financial position as it prepares for upcoming research and development activities. The company's focus remains on advancing its drug delivery platform technology while building shareholder value through continued innovation and intellectual property development. The immediate exercisability of the warrants and their five-year expiration term from the date of effectiveness of the resale registration statement provides additional flexibility for future capital raising activities.